The purpose of the COOL Project was to investigate, review, select and test equipment used for mobile/offsite immunisations. This report explains how School-Based Immunisation Programmes are managing the cold chain and provides information and results from tests of currrent and alternative cold chain equipment and processes. The packing protocol details best practice guidelines arising from the products tested as part of the COOL Project.
WHO Guidance Note
Overall recommendations: National immunization programmes should optimize collaboration and communication with nongovernmental providers regardless of the relative contribution of nongovernmental providers to theh deliverly of vaccination.
In April 2015 the Ministry of Health held a Workshop at the University of Auckland to bring together expertise and those with experience from this epidemic to discuss pertussis disease control strategies and a consistent approach for New Zealand. Gains have been made in the infant primary immunisation series, but pertussis is still a major public health issue. The Ministry of Health wanted to assess the available data and strategies with the aim of minimising the impact of future outbreaks on those most vulnerable.
The recommendations of this report, written by Tim Corbett and funded by GlaxoSmithKline, are aimed at increasing the level of comfort whānau experience in General Practice through proactive, whānau based communication and service enhancement approaches.
Prepared by the Health Quality & Safety Commission for the Child and Youth Mortality Review Committee, the report emphasises the need for existing immunisation programmes to reduce the risk of pertussis in infants, especially those who are Maori, Pacific or under 3 months of age.
Following on from the Adverse effects of vaccines: Evidence and causality report, the Institute of Medicine was tasked, by the Department of Health and Human Services in the U.S., to convene a committee of experts to identify scientific findings and stakeholder concerns about the safety of the current U.S. childhood immunisation schedule and identify research approaches, methodologies, and study designs that could inform this question.
In 2009 the Institute of Medicine was tasked, by the Health Resources and Services Administration in the U.S., to convene a committee of experts to review the epidemiologic, clinical, and biological evidence regarding adverse health events associated with specific vaccines including varicella zoster vaccine; influenza vaccines; hepatitis B vaccine; human papillomavirus vaccine (HPV); tetanus toxoid-containing vaccines other than those containing the whole cell pertussis component; measles, mumps, and rubella vaccines; hepatitis A vaccine; and meningococcal vaccines.